Robert Lee
ID DEMO-007Low Review PriorityLatest assessment 2026-06-14T00:42:56.241014+00:00Messages →Report →Export summary →Decision support only. Consolidates patient data for faster physician review. It does not diagnose, recommend treatment, generate dosing, or replace physician judgment.
Primary phenotype
neuroinflammation
Recovery stage
partial regression
Confidence
61/100
moderate
Clinical improvement
34
functional 32
Phenotype profile
Clinical snapshot
neuroinflammation61%mitochondrial dysfunction
Recovery stage (derived): partial regression — Clinical improvement score 34 (30–44 below baseline).
Top contributors: Brain fog, Short-term memory impairment, Slowed cognitive processing, Headache, Tingling / numbness (neuropathy)
Phenotype engine
All phenotype scores
Co-infection engine
Pattern scores
bartonella0 Low
babesia0 Low
ebv85 High
mold cirs0 Low
mcas0 Low
Lab intelligence
System concern scores
inflammatory27 Mild
immune48 Mild
mitochondrial0 Low
hormonal0 Low
metabolic0 Low
nutritional4 Low
detoxification18 Low
neuroinflammatory49 Mild
connective tissue22 Low
Abnormal: wbc (low), lymphocytes (high), crp (high), esr (high), vitamin d (low), ast (high), alt (high) · Missing: 40
Safety review
Risk flags
No high or critical flags.
Monitoring: Physician review before protocol selection
Missing: pregnancy_status_confirmed, infection_status_confirmed
Outcomes
Baseline vs current
| Metric | Baseline | Current |
|---|---|---|
| fatigue score | 5 | 9 |
| brain fog score | 5 | 8 |
| pain score | 3 | 6 |
| sleep quality score | 6 | 3 |
| pem score | — | — |
| work capacity percent | 60 | 25 |
Knowledge
Phenotype-relevant references
Protocol assets: BPC-157TB-500 / TB4KPVLL-37MOTS-cSS-31GHK-CuIpamorelinCJC-1295
Evidence documents: Neuroinflammation Phenotype: Background (observational)Synergistic Effects of BPC-157, KPV, Thymosin Alpha-1, GHK-Cu, and Targeted Nutritional Cofactors on Bell’s Palsy Reversal in a Facial Nerve Crush Murine Model.docx (expert_opinion)Synergistic Effects of Thymosin Alpha-1, BPC-157, TB-500, LL-37, MOTS-c, SS-31, CJC-1295 with DAC, Ipamorelin, and Nicotine on Lyme Disease Reversal in a Borrelia burgdorferi-Infected Murine Model.docx (expert_opinion)
Dosing references are provider-only and shown in the asset evidence / protocol context, never patient-facing.
Protocol builder
Protocol plans
Provider workspace
Review & notes
Current status: in_progress